共 50 条
The latest advances in the pharmacological management of endometriosis
被引:4
|作者:
Hartner, Gabriel
[1
]
Husslein, Heinrich
[1
]
Kuessel, Lorenz
[1
]
Gstoettner, Manuela
[1
]
Tiringer, Denise
[1
]
Wenzl, Rene
[1
]
Perricos, Alexandra
[1
]
机构:
[1] Med Univ Vienna, Dept Obstet & Gynecol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
关键词:
Endometriosis;
GnRH antagonists;
immunomodulators;
pharmacological treatment;
aromatase inhibitors;
SPRMs;
SERMs;
CHRONIC PELVIC PAIN;
ESTROGEN-RECEPTOR MODULATOR;
CAUSES REGRESSION;
DOUBLE-BLIND;
METFORMIN;
SIMVASTATIN;
AROMATASE;
EXPRESSION;
EFFICACY;
THERAPY;
D O I:
10.1080/14656566.2022.2045274
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Introduction Endometriosis is a benign disease, characterized by a wide range of symptoms and different degrees of severity, which is why therapy should be individually adapted to the patient's needs. Over the years, a lot of research has gone into finding new therapeutic approaches for this enigmatic disease. Areas covered This review presents the latest advances in pharmacological management of endometriosis and is solely focused on studies published from 2010 to 2021 Expert opinion Clinicians and researchers are constantly searching for new therapeutic strategies for endometriosis patients. As there are well-established treatments, however, any new medication should fulfill at least one of the three criteria: increased efficacy, comparable efficacy but a better safety profile, or treatments that have a lack of accompanying contraceptive effects that are seen in most endometriosis treatments. While some new substances show promising results, further studies are needed to demonstrate the fulfillment of one of the above-mentioned criteria.
引用
收藏
页码:121 / 133
页数:13
相关论文